Paolo Tarantino: Decades of cancer research converging on new effective treatment options for our patients with HR-positive breast cancer
Paolo Tarantino, Medical Oncologist and Research Fellow at the Dana-Farber Cancer Institute, shared on LinkedIn:
“We’re finally seeing decades of cancer research converging on new effective treatment options for our patients with hormone receptor-positive breast cancer.
The CDK4/6 inhibitors abemaciclib and ribociclib have shown significant benefits in the adjuvant setting; the first new endocrine treatment, elacestrant, has been approved after 20 years without approvals in this field; the first AKT inhibitor, capivasertib, has entered the clinic; the novel ADCs trastuzumab deruxtecan and sacituzumab govitecan have been approved after demonstrating to improve survival over traditional chemotherapy, and; neoadjuvant immunotherapy with pembrolizumab or nivolumab has shown compelling results on pathologic tumor response, promising to enter the clinic soon.
For a recap and contextualization of these novel options, don’t miss our SABCS23 symposium on HR+ breast cancer, featuring Erika Hamilton, Komal Jhaveri, Hope Rugo and myself, and now available on YouTube.”
View the symposium on YouTube.
Source: Paolo Tarantino/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023